[HTML][HTML] Improved early event-free survival with imatinib in Philadelphia chromosome–positive acute lymphoblastic leukemia: A children's oncology group study
KR Schultz, WP Bowman, A Aledo… - Journal of Clinical …, 2009 - ncbi.nlm.nih.gov
Journal of Clinical Oncology, 2009•ncbi.nlm.nih.gov
Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute
Lymphoblastic Leukemia: A Children's Oncology Group Study - PMC Back to Top Skip to main
content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main
Navigation Search PMC Full-Text Archive Search in PMC Advanced Search User Guide
Journal List J Clin Oncol PMC2773475 Other Formats PDF (206K) Actions Cite Collections
Share Permalink Copy RESOURCES Similar articles Cited by other articles Links to NCBI …
Lymphoblastic Leukemia: A Children's Oncology Group Study - PMC Back to Top Skip to main
content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main
Navigation Search PMC Full-Text Archive Search in PMC Advanced Search User Guide
Journal List J Clin Oncol PMC2773475 Other Formats PDF (206K) Actions Cite Collections
Share Permalink Copy RESOURCES Similar articles Cited by other articles Links to NCBI …
Abstract
Purpose
Imatinib mesylate is a targeted agent that may be used against Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL), one of the highest risk pediatric ALL groups.
ncbi.nlm.nih.gov
